NOVO NORDISK A/S |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 883.2 DKK | +0.07% |
|
+1.16% | +26.51% |
| May. 09 | Health Care Climbs as Obesity-Drug Optimism Returns - Health Care Roundup | DJ |
| May. 09 | News Highlights : Top Company News of the Day - Thursday at 1 PM ET | DJ |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 289B 41.73B | Sales 2025 * | 347B 50.21B | Capitalization | 3,935B 569B |
|---|---|---|---|---|---|
| Net income 2024 * | 104B 14.99B | Net income 2025 * | 126B 18.19B | EV / Sales 2024 * | 13.7 x |
| Net Debt 2024 * | 13.34B 1.93B | Net cash position 2025 * | 12.63B 1.83B | EV / Sales 2025 * | 11.3 x |
| P/E ratio 2024 * |
38.2
x | P/E ratio 2025 * |
31.3
x | Employees | 66,015 |
| Yield 2024 * |
1.33% | Yield 2025 * |
1.6% | Free-Float | 70.17% |
More Fundamentals
* Assessed data
More news
Latest transcript on Novo Nordisk A/S
More recommendations
More press releases
More news
| 1 day | +0.07% | ||
| 1 week | +1.16% | ||
| Current month | -2.15% | ||
| 1 month | +2.97% | ||
| 3 months | +6.17% | ||
| 6 months | +26.99% | ||
| Current year | +26.51% |
1 week
839.30
894.60
1 month
826.70916.90
Current year
688.80932.00
1 year
504.40932.00
3 years
230.60932.00
5 years
155.08932.00
10 years
109.10932.00
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 58 | 90-12-31 | |
| Director of Finance/CFO | 53 | 98-12-31 | |
Stephen Gough
CTO | Chief Tech/Sci/R&D Officer | - | 15-09-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Sylvie Grégoire
BRD | Director/Board Member | 63 | 15-03-18 |
Helge Lund
CHM | Chairman | 61 | 17-03-22 |
Martin MacKay
BRD | Director/Board Member | 68 | 18-02-28 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 21.31% | 0 M€ | +17.22% | ||
| 10.45% | 0 M€ | +11.39% | ||
| 5.40% | 0 M€ | +7.69% | - | |
| 4.67% | 88 M€ | +10.37% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-08 | 883.2 | +0.07% | 2,737,492 |
| 24-05-07 | 882.6 | +3.66% | 9,320,634 |
| 24-05-06 | 851.4 | +0.09% | 1,874,622 |
| 24-05-03 | 850.6 | -2.58% | 5,692,030 |
| 24-05-02 | 873.1 | -2.74% | 4,750,846 |
Delayed Quote Nasdaq Copenhagen, May 08, 2024 at 10:59 am EDT
More quotes
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
Pharmaceuticals
Calendar
2024-08-07
- Q2 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
883.2
DKK
Average target price
908.7
DKK
Spread / Average Target
+2.88%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +26.51% | 568B | |
| +32.36% | 695B | |
| -4.40% | 361B | |
| +19.46% | 330B | |
| +3.50% | 283B | |
| +16.91% | 239B | |
| +8.07% | 204B | |
| -7.61% | 198B | |
| +8.62% | 168B | |
| +4.61% | 125B |
- Stock Market
- Equities
- NOVO B Stock